{"entity":{"id":"geparsixto","kind":"trial","name":"GeparSixto","aka":["GBG 66"],"tldr":"GeparSixto showed that adding carboplatin to chemotherapy given before surgery made triple-negative breast tumours disappear completely far more often, and in longer follow-up cut relapses, which put platinum into the standard neoadjuvant regimen for this type.","summary":"GeparSixto randomised 595 women with early triple-negative or HER2-positive breast cancer to 18 weeks of weekly paclitaxel and non-pegylated liposomal doxorubicin, with bevacizumab for triple-negative and trastuzumab plus lapatinib for HER2-positive disease, with or without weekly carboplatin. The primary endpoint was pathological complete response.\n\nCarboplatin increased the pathological complete response rate in triple-negative disease, and in longer follow-up improved disease-free survival in that group, but did not help HER2-positive disease and added haematological toxicity. Together with CALGB 40603 and later BrighTNess it established carboplatin as part of neoadjuvant chemotherapy for triple-negative breast cancer, the backbone that KEYNOTE-522 then added pembrolizumab to.","status":"positive","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT01426880","url":"https://clinicaltrials.gov/study/NCT01426880"}],"tags":["subtype-trials"],"related":[],"cancers":["tnbc-early","tnbc","breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["carboplatin","paclitaxel","doxorubicin","bevacizumab","trastuzumab","lapatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["gunter-von-minckwitz"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01426880","phase":"2/3","setting":"Early triple-negative and HER2-positive breast cancer: neoadjuvant paclitaxel and non-pegylated liposomal doxorubicin (with bevacizumab in triple-negative and trastuzumab plus lapatinib in HER2-positive disease) with or without carboplatin","sponsor":"German Breast Group (GBG Forschungs GmbH)","result":"Carboplatin increased pathological complete response and improved disease-free survival in triple-negative breast cancer, without benefit in HER2-positive disease.","yearReported":2014,"enrolled":595,"outcomes":[]},"route":"/trials/geparsixto/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"lapatinib","kind":"drug","name":"Lapatinib","route":"/drugs/lapatinib/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"person":[{"id":"gunter-von-minckwitz","kind":"person","name":"Gunter von Minckwitz","route":"/people/gunter-von-minckwitz/"}]}}